MONTREAL, QUEBEC--(Marketwire - November 07, 2007) - MethylGene Inc. (TSX: MYG) today announced its operational and financial results for the third quarter ended September 30, 2007. Highlights - Established a research and development collaboration with Pharmion Corporation for small molecule inhibitors targeting sirtuins for cancer. Sirtuins are a distinct class of histone deacetylase enzymes (Class 3) implicated in cell survival and cell death. Financial terms include approximately U.S. $5 million in research support and up to U.S. $100 million in potential development, regulatory and commercial milestones from Pharmion to MethylGene. MethylGene retains the rights to unselected inhibitors in indications outside of cancer.
